|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Morris JP IV, Wang SC and Hebrok M: KRAS,
hedgehog, Wnt and the twisted developmental biology of pancreatic
ductal adenocarcinoma. Nat Rev Cancer. 10:683–695. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pylayeva-Gupta Y, Grabocka E and Bar-Sagi
D: RAS oncogenes: Weaving a tumorigenic web. Nat Rev Cancer.
11:761–774. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Eser S, Schnieke A, Schneider G and Saur
D: Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer.
111:817–822. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Eser S, Reiff N, Messer M, Seidler B,
Gottschalk K, Dobler M, Hieber M, Arbeiter A, Klein S, Kong B, et
al: Selective requirement of PI3K/PDK1 signaling for Kras
oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell.
23:406–420. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Collisson EA, Trejo CL, Silva JM, Gu S,
Korkola JE, Heiser LM, Charles RP, Rabinovich BA, Hann B, Dankort
D, et al: A central role for RAF→MEK→ERK signaling in the genesis
of pancreatic ductal adenocarcinoma. Cancer Discov. 2:685–693.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lim KH, Baines AT, Fiordalisi JJ,
Shipitsin M, Feig LA, Cox AD, Der CJ and Counter CM: Activation of
RalA is critical for Ras-induced tumorigenesis of human cells.
Cancer Cell. 7:533–545. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Feldmann G, Mishra A, Hong SM, Bisht S,
Strock CJ, Ball DW, Goggins M, Maitra A and Nelkin BD: Inhibiting
the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation
and progression through the suppression of Ras-Ral signaling.
Cancer Res. 70:4460–4469. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dhaka A, Costa RM, Hu H, Irvin DK, Patel
A, Kornblum HI, Silva AJ, O'Dell TJ and Colicelli J: The RAS
effector RIN1 modulates the formation of aversive memories. J
Neurosci. 23:748–757. 2003.PubMed/NCBI
|
|
11
|
Mohelnikova-Duchonova B, Kocik M,
Duchonova B, Brynychova V, Oliverius M, Hlavsa J, Honsova E,
Mazanec J, Kala Z, Ojima I, et al: Hedgehog pathway overexpression
in pancreatic cancer is abrogated by new-generation taxoid
SB-T-1216. Pharmacogenomics J. Aug 30–2016.(Epub ahead of print).
PubMed/NCBI
|
|
12
|
Mohelnikova-Duchonova B, Brynychova V,
Hlavac V, Kocik M, Oliverius M, Hlavsa J, Honsova E, Mazanec J,
Kala Z, Melichar B and Soucek P: The association between the
expression of solute carrier transporters and the prognosis of
pancreatic cancer. Cancer Chemother Pharmacol. 72:669–682. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mohelnikova-Duchonova B, Brynychova V,
Oliverius M, Honsova E, Kala Z, Muckova K and Soucek P: Differences
in transcript levels of ABC transporters between pancreatic
adenocarcinoma and nonneoplastic tissues. Pancreas. 42:707–716.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Soucek P, Anzenbacher P, Skoumalova I and
Dvorak M: Expression of cytochrome P450 genes in CD34+
hematopoietic stem and progenitor cells. Stem Cells. 23:1417–1422.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mohelnikova-Duchonova B, Oliverius M,
Honsova E and Soucek P: Evaluation of reference genes and
normalization strategy for quantitative real-time PCR in human
pancreatic carcinoma. Dis Markers. 32:203–210. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bustin SA, Benes V, Garson JA, Hellemans
J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL,
et al: The MIQE guidelines: Minimum information for publication of
quantitative real-time PCR experiments. Clin Chem. 55:611–622.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Caldas C, Hahn SA, Hruban RH, Redston MS,
Yeo CJ and Kern SE: Detection of K-ras mutations inthe stool of
patients with pancreatic adenocarcinoma and pancreatic ductal
hyperplasia. Cancer Res. 54:3568–3573. 1994.PubMed/NCBI
|
|
19
|
Bournet B, Buscail C, Muscari F, Cordelier
P and Buscail L: Targeting KRAS for diagnosis, prognosis, and
treatment of pancreatic cancer: Hopes and realities. Eur J Cancer.
54:75–83. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou L, Baba Y, Kitano Y, Miyake K, Zhang
X, Yamamura K, Kosumi K, Kaida T, Arima K, Taki K, et al: KRAS,
BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic
cancers: Pyrosequencing technology and literature review. Med
Oncol. 33:322016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Oliveira-Cunha M, Hadfield KD, Siriwardena
AK and Newman W: EGFR and KRAS mutational analysis and their
correlation to survival in pancreatic and periampullary cancer.
Pancreas. 41:428–434. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schultz NA, Roslind A, Christensen IJ,
Horn T, Høgdall E, Pedersen LN, Kruhøffer M, Burcharth F, Wøjdemann
M and Johansen JS: Frequencies and prognostic role of KRAS and BRAF
mutations in patients with localized pancreatic and ampullary
adenocarcinomas. Pancreas. 41:759–766. 2012.PubMed/NCBI
|
|
23
|
Lemstrova R, Melichar B and
Mohelnikova-Duchonova B: Therapeutic potential of taxanes in the
treatment of metastatic pancreatic cancer. Cancer Chemother
Pharmacol. 78:1101–1111. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Melichar B: Laboratory medicine and
medical oncology: The tale of two Cinderellas. Clin Chem Lab Med.
51:99–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fuchs CS, Azevedo S, Okusaka T, Van
Laethem JL, Lipton LR, Riess H, Szczylik C, Moore MJ, Peeters M and
Bodoky G: A phase 3 randomized, double-blind, placebo-controlled
trial of ganitumab or placebo in combination with gemcitabine as
first-line therapy for metastatic adenocarcinoma of the pancreas:
The GAMMA trial. Ann Oncol. 26:921–927. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Deplanque G, Demarchi M, Hebbar M, Flynn
P, Melichar B, Atkins J, Nowara E, Moyé L, Piquemal D, Ritter D, et
al: A randomized, placebo-controlled phase III trial of masitinib
plus gemcitabine in the treatment of advanced pancreatic cancer.
Ann Oncol. 26:1194–1200. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chuang HC, Huang PH, Kulp SK and Chen CS:
Pharmacological strategies to target oncogenic KRAS signaling in
pancreatic cancer. Pharmacol Res. 117:370–376. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chung V, McDonough S, Philip PA, Cardin D,
Wang-Gillam A, Hui L, Tejani MA, Seery TE, Dy IA, Al Baghdadi T, et
al: Effect of Selumetinib and MK-2206 vs oxaliplatin and
fluorouracil in patients with metastatic pancreatic cancer after
prior therapy: SWOG S1115 study randomized clinical trial. JAMA
Oncol. 3:516–522. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Riely GJ, Johnson ML, Medina C, Rizvi NA,
Miller VA, Kris MG, Pietanza MC, Azzoli CG, Krug LM, Pao W and
Ginsberg MS: A phase II trial of Salirasib in patients with lung
adenocarcinomas with KRAS mutations. J Thoracic Oncol. 6:1435–1437.
2011. View Article : Google Scholar
|
|
30
|
Karp JE, Vener TI, Raponi M, Ritchie EK,
Smith BD, Gore SD, Morris LE, Feldman EJ, Greer JM, Malek S, et al:
Multi-institutional phase 2 clinical and pharmacogenomic trial of
tipifarnib plus etoposide for elderly adults with newly diagnosed
acute myelogenous leukemia. Blood. 119:55–63. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rao S, Cunningham D, de Gramont A,
Scheithauer W, Smakal M, Humblet Y, Kourteva G, Iveson T, Andre T,
Dostalova J, et al: Phase III double-blind placebo-controlled study
of farnesyl transferase inhibitor R115777 in patients with
refractory advanced colorectal cancer. J Clin Oncol. 22:3950–3957.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Van CE, van de Velde H, Karasek P, Oettle
H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C,
Neumann H, et al: Phase III trial of gemcitabine plus tipifarnib
compared with gemcitabine plus placebo in advanced pancreatic
cancer. J Clin Oncol. 22:1430–1438. 2004. View Article : Google Scholar : PubMed/NCBI
|
